Alisertib Completed Phase 1 Trials for Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Refractory Mantle Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma / Refractory Follicular Lymphoma / MYC Positive / Refractory Hodgkin Lymphoma / Recurrent Follicular Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / Refractory Burkitt Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / Recurrent Hodgkin Lymphoma / Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Treatment